The Medicines and Healthcare products Regulatory Agency (MHRA) has celebrated 10 years of global collaboration.
This year represents a decade since the MHRA joined seven other regulators to establish the International Coalition of Medicines Regulatory Authorities (ICMRA).
ICMRA’s biggest achievement remains its cooperation throughout the pandemic, with the MHRA being the first member to approve the vaccine developed by Pfizer/BioNTech for UK use.
Since its founding though, the ICMRA has worked together to achieve a range of different milestones in areas such as antimicrobial resistance and clinical trials, all the way to pharmacovigilance and regulatory convergence.
“Over the past ten years, as a founding member of ICMRA, we’ve demonstrated how international collaboration can address major health challenges around the world.”
The future will see ICMRA collaborate further to address current and emerging challenges in their industry.
MHRA chief executive, Dr June Raine, added: “Through strong collaboration across ICMRA, we’re able to share our national knowledge to make a global impact, supporting streamlined regulatory processes and ensuring patients worldwide have access to safe and effective healthcare products.”
The ICMRA now boasts as many as 38 members and will celebrate its 10th anniversary at the annual summit and plenary in Melbourne on 13-16 November.
During the summit, the MHRA will take part in discussions around artificial intelligence and machine learning, as well as medical products based on genes, cells or tissue engineering.
Image credit: iStock
